We have recently identified glucose-regulated protein-78 (GRP78) as a relevant molecular target expressed in metastatic tumors by fingerprinting the circulating repertoire of antibodies from cancer patients. Here we design and evaluate a ligand-receptor system based on the tumor cell membrane expression of GRP78. We show that GRP78 binding peptide motifs target tumor cells specifically in vivo and in human cancer specimens ex vivo. Moreover, synthetic chimeric peptides composed of GRP78 binding motifs fused to a programmed cell death-inducing sequence can suppress tumor growth in xenograft and isogenic mouse models of prostate and breast cancer. Together, these preclinical data validate GRP78 on the tumor cell surface as a functional molecular target that may prove useful for translation into clinical applications.
Introduction
teractions in solid phase, cell lines, xenograft and isogenic tumor models in mice, and human cancer specimens.
Here we introduce two ligand peptides that can specifically The membrane compartment of cells in tumors contains many receptors that are required for their survival. In particular, mem-
(1) bind to GRP78 in a cell-free system, (2) target cell surfaces in vitro, (3) home in vivo to tumors in mouse models of breast bers of the unfolded protein response (Kaufman, 1999; Lee, 2001; Reddy et al., 2003) , such as the glucose-regulated protein and prostate cancer, (4) suppress tumor growth when synthesized as a fusion chimeric peptide with a proapoptotic seand the heat shock protein families, are candidate targets on the tumors; the presence and functionality of this subset of quence, and finally (5) bind to patient-derived cancer samples. Together, these data indicate that GRP78 is a functional molecuchaperone proteins in signal transduction, drug resistance, apoptosis, and immunomodulation has recently begun to be recoglar target on tumor cell surfaces in vivo. This ligand-receptor system may yield targeted therapy applications and should be nized (Beere et al., 2000; Lee, 2001; Kamal et al., 2003; Mintz et al., 2003; Neckers and Lee, 2003; Nicchitta, 2003 ; Ravagnan considered for validation against primary and metastatic tumors. et al., 2001; Reddy et al., 2003; Shin et al., 2003) .
By screening combinatorial peptide libraries, we identified one such glucose-regulated protein family member, glucoseResults regulated protein-78 kDa (GRP78), as a tumor antigen through epitope mapping of the humoral immune response from cancer Choice of GRP78 binding peptides and initial evaluation of targeting vectors patients . Because GRP78 confers a protective cellular response against stress conditions present in solid
To design the targeting vectors that were used here, we evaluated a panel of four predicted GRP78 binding motifs (Blondtumors (Jamora et al., 1996; Koong et al., 1994; Li et al., 1992; Miyake et al., 2000; Reddy et al., 2003; Sugawara et al., 1993) , Elguindi et al., 1993) in phage binding assays. Among the consensus peptide motifs tested in our phage-targeting system, we hypothesized that GRP78 expressed on the cell surface of cancer cells Shin et al., 2003) could serve the ligand peptides WIFPWIQL and WDLAWMFRLPVG showed the best targeting activity and specificity to GRP78, relative as a functional receptor in vivo. In order to evaluate whether GRP78 ligands would allow targeting of solid tumors, we deto control proteins (Supplemental Figure S1 at http://www. cancercell.org/cgi/content/full/6/3/275/DC1). Given the binding vised experiments to assess GRP78-based protein-protein in- GRP78, HSP70, HSP90, or BSA was coated on microtiter wells at 10 g/ml and incubated with either WIFPWIQL-phage (A) or WDLAWMFRLPVGphage (B). An insertless phage (fd-tet) served as the negative control. Phage input was 10 9 TU per well. Results are expressed as mean Ϯ standard error of the mean (SEM) of triplicate wells. Binding inhibition of WIFPWIQL-phage (C) and WDLAW MFRLPVG-phage (D) to immobilized GRP78 was obtained by the addition of the corresponding synthetic peptides. Microtiter wells were coated with GRP78 at 10 g/ml, and phage clones were incubated with increasing concentrations of synthetic cognate or control peptides. Experiments were performed three times with similar results. *Student's t test, p Ͻ 0.01.
properties of these peptides, we decided to use fUSE5-derived ure 2, left panels), recombinant GRP78 in solution ( Figure 2 , phage vector constructs displaying the GRP78 binding motifs middle panels), or the corresponding synthetic peptides ( Figure  WIFPWIQL and WDLAWMFRLPVG as fusion peptides to the 2, right panels) inhibited binding. Control isotypic antibodies, minor coat protein pIII (Smith and Scott, 1993) for further experiunrelated control proteins, and peptides did not affect binding ments.
of the GRP78 binding phage. These results indicate that GRP78 binding peptides can specifically target cell surfaces. Cell-free binding of ligand peptides to immobilized GRP78 is specific GRP78 binding peptides undergo cell internalization We evaluated binding of WIFPWIQL-phage ( Figure 1A ) and of Next, we evaluated whether GRP78 would mediate internaliza-WDLAWMFRLPVG-phage ( Figure 1B ) to recombinant GRP78 tion of a ligand into cells. We used the DU145 line as representain microtiter wells. Both WIFPWIQL-phage and WDLAWMF RLPVG-phage bound significantly more to GRP78 in vitro than to control proteins, including heat shock protein 70 (HSP70), heat shock protein 90 (HSP90), and bovine serum albumin (BSA). Moreover, WIFPWIQL-phage (870-fold; Student's t test, p Ͻ 0.001) and WDLAWMFRLPVG-phage (260-fold; Student's t test, p Ͻ 0.001) bound significantly more to immobilized GRP78 in vitro than did a negative control phage displaying no insert (fdtet). We observed a dose-dependent inhibition of WIFPWIQLphage ( Figure 1C ) and WDLAWMFRLPVG-phage ( Figure 1D ) binding to GRP78 by the corresponding synthetic peptides; control peptides with unrelated sequences had no detectable effect. Together, these data show that ligand peptides displayed in a filamentous phage specifically bind to immobilized GRP78.
GRP78 binding peptides target cell surfaces in vitro
Having determined the specificity of GRP78 binding peptides to the immobilized protein in a cell-free system, we next evaluated binding to human DU145 prostate cancer cells (Figure 2 ). Binding of filamentous phage clones displaying WIFPWIQL ( Figure  2A ) and WDLAWMFRLPVG ( Figure 2B ) to intact tumor cells was performed by using an aqueous-organic phase separation assay Giordano et al., 2001) . Each of the GRP78 binding phage clones The BRASIL method (Giordano et al., 2001 ) was applied to test the binding or insertless negative control phage was incubated with DU145 of WIFPWIQL-phage, WDLAWMFRLPVG-phage, or control insertless phage to the human prostate cancer-derived DU145 cells. Transducing unit counts cells. Binding to DU145 cells was at least 30-fold higher (Stuof the GRP78 binding clones without inhibition was set to 100% in each case.
tive human prostate cancer-derived cells expressing GRP78 on the cell surface and GRP78 binding phage as targeted ligands. Each phage clone or control phage was incubated with cells for 4 hr at 37ЊC. Cells were washed to remove noninternalized phage, permeabilized, and stained with an anti-bacteriophage antibody. A Cy 3 -conjugated secondary antibody was used to detect the presence and localization of phage particles. GRP78-targeted phage internalization was temperature dependent and time dependent, being detectable at 8 hr and peaking at 24 hr (data not shown). Both WIFPWIQLphage and WDLAWMFRLPVG-phage were internalized into DU145 cells; only background fluorescence was observed when nonpermeabilized cells or nontargeted control phage ( Figure  3A ) were used as negative controls. These results indicate that the binding peptides WIFPWIQL and WDLAWMFRLPVG can mediate the internalization of GRP78-targeted phage into cells. Moreover, in order to show that the internalization of GRP78 binding ligands can also occur outside of the context of targeted phage constructs, we have also evaluated cell killing in vitro by the synthetic GRP78 binding peptide WDLAWMFRLPVG fused to the programmed cell death-inducing domain D (KLAKLAK) 2 , an amphipatic ␣ helix-forming antimicrobial peptide (Javadpour et al., 1996) that preferentially disrupts eukaryotic mitochondrial membranes upon receptor-mediated internalization (Arap et al., 2002b; Ellerby et al., 1999; Kolonin et al., 2004; Zurita et al., 2004) . Increasing concentrations of either WDLAWMFRLPVG-GG-D (KLAKLAK) 2 or negative control peptides [an equimolar admixture of WDLAWMFRLPVG plus D (KLAKLAK) 2 ] were incubated with DU145 cells at 37ЊC, and viability was assessed over time. To gain insight into the mechanism of peptide internalization, we also determined whether endocytosis and GRP78 recycling could be affected by ATPase inhibitors (Schmid and Carter, ficed, and the tumors and several control organs were collected and analyzed for phage staining. We observed strong tumor staining for each GRP78 binding phage clone, while only background staining was detected in control organs; moreover, negcell death-inducing domain (Arap et al., 2002b ; Ellerby et al., ative control phage was not detected in tumors or several control 1999; Kolonin et al., 2004; Zurita et al., 2004) would have antituorgans ( Figure 4 ). It is of note that, as part of the reticulomor effects in vivo. We used nude mice bearing DU145-derived endothelial system, hepatic and splenic tissues clear circulating human prostate cancer xenografts ( Figures 5A and 5B) or immuparticles (such as phage) nonspecifically and independently of nocompetent Balb/c mice bearing EF43-fgf4-derived isogenic the peptides displayed. These data show that human prostate tumors (Figures 5C and 5D Insertless phage fd-tet (negative control), RGD-4C phage (positive control), or phage displaying the GRP78 binding peptides WIFPWIQL and WDLAWMFRLPVG were intravenously administered into mice bearing DU145-derived prostate carcinoma xenografts. Phage clones were allowed to circulate for 24 hr, and tissues were recovered and stained as described in the Experimental Procedures. A strong phage staining was observed with WIFPWIQL-phage or WDLAWMFRLPVG-phage in tumor xenografts. Little or no staining was observed either with fd-tet phage or with GRP78 binding phage clones in control organs. Scale bar, 100 m.
pression of tumor growth was slightly less efficient in mice studied regardless of whether or not they were tumor cells (Supplemental Figure S2 at http://www.cancercell.org/cgi/conbearing EF43-fgf4 tumors, likely reflecting the aggressiveness of the model. Tumors in mice treated by equimolar mixtures of tent/full/6/3/275/DC1). These contrasting results indicate that GRP78-mediated cell death in vitro (Supplemental Figure S2 ) either WIFPWIQL plus D (KLAKLAK) 2 or WDLAWMFRLPVG plus D (KLAKLAK) 2 behaved similarly to those tumors in mice that does not recapitulate the selective induction of tumor cell apoptosis in vivo ( Figure 5 ); such paradox might be due to the received vehicle only, indicating that untargeted D (KLAKLAK) 2 with GRP78 binding peptides had no detectable effect on tumor upregulation of stress response proteins (such as GRP78, one of the hallmarks of the unfolded protein response), which is growth.
likely to occur in cells grown in vitro, outside of their optimal in vivo physiological conditions. In fact, very recently it became GRP78-mediated cell apoptosis in vitro does not model clear that GRP78 promoter-driven expression of a reporter therapeutic in vivo targeting transgene is undetectable in all the major organs evaluated in To address whether the presence of GRP78 as a target on the adult mice (such as liver, spleen, kidney, brain, lung, heart, and cell surface is related to the unfolded protein response (Kaufpancreas); in contrast, the GRP78 promoter is highly active man, 1999; Lee, 2001; Reddy et al., 2003) rather than an inherent in tumors (Dong et al., 2004) . Consistently, we have detected feature of tumors per se, we examined both malignant and programmed cell death induction by TUNEL staining in DU145-nonmalignant cells in vitro. First, we performed fluorescencederived tumor xenografts but not in control organs, in agreement activated cell surface (FACS) analysis of a representative panel with GRP78 promoter studies in tumor-bearing mice (Suppleof human and mouse cell lines, including tumor cells of epithelial mental Figure S3 ; Dong et al., 2004) . and nonepithelial origin, as well as nonmalignant cells. We detected positive surface staining, indicating broad membrane expression of GRP78 in all the lines cultured in vitro (data not GRP78 binding phage clones recognize human prostate cancer samples shown). Next, to confirm the functional relevance of the surface expression of GRP78, we have evaluated targeted cell killing in Because we found GRP78 expression to be high in human prostate cancer , we used phage overlay vitro by GRP78 binding peptides chimerized with the D (KLAKLAK) 2 proapoptotic motif (Arap et al., 2002b; Ellerby et al., 1999; Koassays (Arap et al., 2002a; Zurita et al., 2004) to determine whether the GRP78-targeting phage would bind to bone marrow lonin Zurita et al., 2004) . Consistently, as cultured cells grown in vitro appear to express GRP78 at the membrane metastases from patient-derived prostate cancer. To evaluate whether the GRP78 binding phage could inhibit the anti-GRP78 level, we have observed programmed cell death in all cell lines GRP78 antibody, whereas a negative control phage with no peptide did in mice treated with the GRP78-targeted proapoptotic peptides relative to not affect the staining of the anti-GRP78 antibody (E). An eosin staining of vehicle or to the corresponding control peptides.
the tumor is shown in F. Scale bar, 100 m.
antibody staining, WIFPWIQL-phage, WDLAWMFRLPVG-phage, tochemistry observations. GRP78-targeted phage clones disand negative control phage were overlaid on serial human tissue playing either WIFPWIQL or WDLAWMFRLPVG peptides clearly sections prior to adding the anti-GRP78 antibody or negative stained prostate cancer tissue, whereas negative control phage control antibody. Consistently, markedly reduced antibody stainshowed only background staining; GRP78 expression verified ing was observed with each GRP78 binding phage clone but with an anti-GRP78 antibody served as a positive control ( Figure  not with the negative control phage (Figure 6 ). Moreover, in a 8). Taken together, these results indicate that GRP78-based reverse experiment, each GRP78 binding phage or negative ligand-receptor interactions in the context of human prostate control phage was overlaid on serial human tissue sections.
cancer progression are specific. After extensive washing to remove nonspecific binding, samples were incubated with an anti-bacteriophage antibody. We obDiscussion served a strong staining with the GRP78 binding phage clones and marked inhibition when an anti-GRP78 antibody was added Discovery of functional ligand-receptor systems is a critical step to the slide; in contrast, no inhibition was observed with a control for the development of targeted therapies. Several lines of eviantibody (Figure 7) . dence have recently emerged to suggest that stress response Finally, to evaluate the expression of GRP78 during the proteins present on the surface of tumor cells may serve as progression of prostate cancer, we are currently characterizing molecular targets. First, global profiling of the cell surface prothe expression of GRP78 in a panel of human prostate cancer teome of tumor cells has disclosed a relative abundance of samples during different tumor stages, including organ-conchaperone heat shock and glucose-regulated proteins (Shin et fined, locally advanced, and metastatic disease. Preliminary imal., 2003) . Second, fingerprinting the repertoire of antibodies munohistochemistry analysis suggests that GRP78 can be exderived from cancer patients with phage display random peptide pressed even in early stage prostate cancer, that stage-specific libraries has identified a conformational mimic motif of one such upregulation of this target can occur, and that the expression glucose-regulated protein family member, GRP78, in prostate of GRP78 is strong in metastatic disease (unpublished data). Overlay assays were again in agreement with such immunohiscancer. Antibodies against this peptide revealed cell surface Serial tissue sections of bone marrow metastases from human prostate cancer were incubated with an anti-GRP78 antibody prior to adding the WIFPWIQL-phage, WDLAWMFRLPVG-phage, and negative control phage (fd-tet) to the sections. Strong staining was observed when the phage was applied with no antibody (A and D) or with negative control antibody (B and E). In contrast, marked reduction in phage staining was observed with anti-GRP78 antibody (C and F). Scale bar, 100 m.
expression of GRP78 . Third, GRP78 exmanner, indicating that the interaction between the ligands and GRP78 is specific. Next, we established that WIFPWIQL-phage pressed on the surface of prostate cancer cells appears to mediate the signal transduction of ␣ 2 -macroglobulin (Misra et and WDLAWMFRLPVG-phage clones target GRP78 expressed on the cell membrane and are likely internalized by an active al., 2002), a plasma protease inhibitor that binds to prostatespecific antigen (PSA) as well (Kanoh et al., 2001 ). Fourth, we receptor-mediated process. Moreover, to establish whether the GRP78 binding phage have shown that the humoral response elicited against the GRP78-mimic motif or against the native GRP78 strongly correcould home to human prostate cancer xenografts or mouse breast isogenic tumors in vivo, we administered the phage conlated with the development of androgen-independent disease and shorter overall survival in a large population of prostate structs and controls intravenously into tumor-bearing mice. At 24 hr, we observed localization of GRP78 binding phage into cancer patients . Fifth, GRP78 is overexpressed under conditions often found in tumors (such as ischthe tumors, with barely detectable phage localization to several control organs. The staining pattern observed in vivo indicates emia, hypoxia, or glucose deprivation), hence its denomination as a glucose-regulated stress response protein that plays a that GRP78-mediated targeted phage internalization occurred in tumor cells. In fact, selective accessibility based on the fenescentral role in the general cellular defense mechanism that is referred to as the unfolded protein response (Kaufman, 1999;  trated and abnormal nature of tumor vasculature might allow for preferential targeting of tumor cells by GRP78-targeted pro- Lee, 2001; Reddy et al., 2003) . Together, these observations led to efforts to evaluate GRP78 on the tumor cell membrane as apoptotic peptides (Hashizume et al., 2000) . We then tested the therapeutic properties of the GRP78 binding peptides linked a translational target for therapeutic intervention in the context of tumors such as metastatic prostate or breast cancers, currently to a proapoptotic motif (Arap et al., 2002b; Ellerby et al., 1999; Kolonin et al., 2004; Zurita et al., 2004) in vivo. Paradoxically, incurable diseases.
Here, we designed and validated GRP78-based systems for the GRP78-targeted proapoptotic peptides used in this work seem to promote programmed cell death in vitro in malignant as ligand-directed targeting of solid tumors, in particular of prostate and breast cancer. We generated phage displaying GRP78 bindwell as nonmalignant cells; in contrast, the apoptotic induction observed in vivo is clearly tumor specific. These data are relevant ing peptides by cloning the inserts WIFPWIQL and WDLAWM FRLPVG into a phage construct and then we studied the properbecause they illustrate that the effects observed are not dependent on the origin of the tumor cells (human versus mouse), ties of these phage clones. First, WIFPWIQL-phage and WDL AWMFRLPVG-phage bound significantly more to GRP78 than tumor type (prostate cancer versus breast cancer), or immune status of the host (nude mice versus immunocompetent mice). to related and unrelated control proteins. We also showed that the synthetic WIFPWIQL and WDLAWMFRLPVG peptides inAntitumor effects of GRP78-targeted proapoptotic peptides were equally effective in both models: significant reduction in hibit binding of the corresponding phage in a dose-dependent Relative to the weak staining observed with a negative control phage (A), strong staining was observed with either WDLAWMFRLPVG-phage (B), WIFPWIQL-phage (C), or anti-GRP78 antibody (D), which also served as a positive control for GRP78 expression.
tumor volumes when prostate cancer xenografts or murine support to the idea of exploiting the differential humoral immune response to human cancer Vidal et al., 2004 ) breast isogenic tumors were treated with the targeted peptides relative to controls was observed. In agreement with such findas a promising methodology for identifying targets for therapeutic intervention. ings and the recent GRP78 promoter studies of other investigators (Dong et al., 2004) , we did not detect apoptosis induction
Experimental procedures
in normal tissues upon administration of the GRP78-targeted proapoptotic peptides. Also, preliminary preclinical studies have
Cell culture and reagents
shown that the maximum tolerated dose (MTD) for these pep-DU145 prostate cancer cells were purchased from the American Type Cultides has not yet been reached (unpublished data), again reinture Collection (ATCC; Manassas, VA), and tissue culture was performed forcing the notion that GRP78 is selectively targeted in our tumor as described (Mickey et al., 1977) . EF43-fgf4 cells have been described (Deroanne et al., 1997; Hajitou et al., 2001 Marchiò et al., 2004 ). All models. Thus, this apparent limitation of in vitro models in this soluble peptides were produced by Merrifield synthesis (AnaSpec, San Jose, experimental system suggests that evaluation of GRP78-tar-CA and Genemed Synthesis, Inc., South San Francisco, CA). Unless othergeted treatment in mouse tumor models is more likely to be wise specified, synthetic peptides with unrelated sequences were used as representative of clinically relevant aspects of disease in human a negative control in binding experiments.
cancer and is entirely consistent with the in vivo work of Dong et al. (2004) .
Generation of targeting vectors
DNA sequences encoding the GRP78 binding peptide motifs WIFPWIQL or Finally, GRP78 binding peptides also targeted human pros-WDLAWMFRLPVG (Blond-Elguindi et al., 1993) were cloned into SfiI-digested tate cancer (both organ-confined and metastatic to the bone fUSE5 phage vectors (Smith and Scott, 1993) . Briefly, 500 ng of each of the marrow), as shown by phage overlay assays (Arap et al., 2002a;  synthetic oligonucleotide templates corresponding to the displayed peptides Zurita et al., 2004) . Serial sections from human prostate cancer (Sigma-Genosys, Woodlands, TX) were converted to double-stranded DNA at early or advanced stages yielded stronger staining when by PCR amplification with the primer set 5ЈGTGAGCCGGCTGCCC3Ј and exposed to GRP78 binding phage clones than when exposed 5ЈTTCGGCCCCAGCGGC3Ј (Sigma-Genosys) and 2.5 U of Taq-DNA polymerase (Promega, Madison, WI) in 20 l as follows: 94ЊC for 2 min, followed to control phage, reflecting the differential expression of GRP78 by 35 cycles at 94ЊC for 30 s, 60ЊC for 30 s, and 72ЊC for 30 s, followed in the progression of prostate cancer. GRP78 binding phage by 72ЊC for 5 min. Double-stranded DNA sequences that contained BglI clones abrogate the binding of an anti-GRP78 antibody, prerestriction sites in the insert-flanking regions were purified by using a QIAsumably due to the relatively large size of phage particles that quick nucleotide removal kit (Qiagen, Hilden, Germany) and eluted from can block access to the antigen. Consistently, an anti-GRP78 each QIAquick column (Qiagen) by 50 l washes with ddH 2 O. Oligonucleoantibody also blocked the staining of GRP78 binding phage. tides were digested with BglI for 2 hr at 37ЊC, repurified, and ligated into One might speculate on some additional aspects of the work SfiI-digested fUSE5 vector. Plasmids were electroporated into MC1061 E. coli. DNA from each of the phage clones generated was PCR amplified presented here. Compared to other targets isolated by using to verify the correct insertion and nucleotide sequence. phage display, a potential advantage of GRP78 is that its expression might allow not only ligand-directed but also transcriptional Cell-free binding assay tumor targeting. It remains the focus of our ongoing studies to GRP78, HSP70, HSP90 (all from Stressgen, Victoria, Canada), and BSA characterize whether specific tumor-associated GRP78 feawere immobilized on microtiter wells of 96-well plates overnight at 4ЊC. Wells tures (such as isoforms, chaperoned coreceptors, or differential were washed twice with phosphate-buffered saline (PBS), blocked with PBS containing 3% BSA for 1 hr at room temperature (RT), and incubated with activation states) might be present in the cell surface. Indeed, 10 9 transducing units (TU) of WIFPWIQL-phage, WDLAWMFRLPVG-phage, a recent study has shown that a fraction of GRP78 can exist or insertless control phage in 50 l of PBS containing 1.5% BSA. After 2 hr as a transmembrane protein capable of trafficking to tumor cell at RT, wells were washed with PBS and bound phage clones were recovered surfaces (Reddy et al., 2003) ; thus, it is plausible that GRP78
by infection with host bacteria (log phase E. coli K91 kan; OD 600 Ϸ 2). Aliquots might return to the cell surface after internalization occurs, as of the bacterial culture were plated onto Luria-Bertani (LB) agar plates conpart of a dynamic process. In yet other lines of research, GRP78
taining 40 g/ml tetracycline and 100 g/ml kanamycin (Smith and Scott, 1993; . Plates were incubated overnight at 37ЊC, and has also been identified by phage display on the surfaces of inflammatory diseases. If so, consideration should be given to selection of improved GRP78 ligands such as higher-affinity
Cell surface binding assay
We used the biopanning and rapid analysis of selective interactive ligands single-chain antibodies (Adams et al., 1998; Tarli et al., 1999;  (BRASIL) method (Giordano et al., 2001 ) to evaluate phage binding to intact Viti et al., 1999) , as an alternative or in addition to peptides or cells. In brief, cultured human prostate cancer-derived DU145 cells were peptidomimetics.
detached with ethylenediaminetetraacetate (EDTA) and resuspended in DulIn summary, these data establish GRP78 expressed in the becco's modified Eagle's medium (DMEM) containing 1% BSA at 4 ϫ 10 6 cell surface as a tumor target in human prostate cancer, in line cells per ml. The cell suspension (50 l) was incubated with 10 9 TU of with the renewed interest in stress response proteins in prostate WIFPWIQL-phage, WDLAWMFRLPVG-phage, or insertless control phage at 4ЊC in constant slow rotation. After 2 hr, the phage/cell mixture (aqueous cancer (Cornford et al., 2000; Lebret et al., 2003a ) and other phase) was gently transferred to the top of a nonmiscible organic phase urological tumors (Lebret et al., 2003b) . Other membrane-asso- response proteins. On a larger context, this study lends further and an unrelated isotype control antibody at the same dilution, recombinant dine (DAB; DAKO). Counterstaining was achieved by a 20 s immersion in GRP78 (Stressgen), unrelated control proteins, and synthetic cognate or 100% hematoxylin, and the slides were dehydrated (with graded alcohols control peptides (each at 100 g/ml) were used to evaluate competitive and xylene) and mounted. All sections and controls from each specimen were inhibition of phage binding.
included in simultaneous staining runs to minimize experimental variability.
Cell internalization assay
Targeted proapoptotic peptide treatment of tumor-bearing mice Cells were grown in tissue chamber slides (Lab-Tek II Chamber Slide System; Cohorts of tumor-bearing mice were size matched and divided into groups Nalge Nunc International Corp., Naperville, IL), washed twice with PBS, (n ϭ 7 each), and treatments started when mean tumor volumes reached incubated with 10 9 TU of WIFPWIQL-phage, WDLAWMFRLPVG-phage, or ‫002ف‬ mm 3 ; the weights of mice were also similar (Ͻ5% variation) within insertless control phage in DMEM containing 1% BSA at 37ЊC, and washed each treatment cohort. Two GRP78-targeting peptides (WIFPWIQL or five times with PBS to remove unbound phage after 4 hr incubation. Bound WDLAWMFRLPVG) were each synthesized as a chimera with the proapophage clones to cell membranes were chemically eluted by rinsing cells with ptotic motif D (KLAKLAK) 2 and used as therapy in tumor-bearing mice while 20 mM glycine at pH 2.3. Next, cells were washed three times with PBS, control tumor-bearing mice received a corresponding equimolar mixture of fixed with PBS containing 4% paraformaldehyde (PFA) at RT for 15 min, either unconjugated WIFPWIQL plus D (KLAKLAK) 2 or unconjugated WDL washed with PBS, permeabilized with 0.2% Triton X-100, washed with PBS, AWMFRLPVG plus D (KLAKLAK) 2 . Mice were deeply anesthetized, and tumor and blocked with PBS containing 1% BSA. Cells were then incubated with volumes were measured as described (Arap et al., 1998 ; Koivunen et al., a 1:200 dilution of the primary anti-M13 bacteriophage antibody (Amersham, 1999; Marchiò et al., 2004; IgG-reagent grade; Sigma, St. Louis, MO) at the same immunoglobulin conRoche, Mannheim, Germany). All samples were performed in triplicates.
centration were used to evaluate competitive inhibition of phage binding. Tissue sections were incubated with media alone, anti-GRP78 antibody, or Establishment of tumor-bearing mice control antibody at the same immunoglobulin concentration for 1 hr at RT. Immunodeficient male athymic nu/nu (nude) mice were commercially obNext, 2 ϫ 10 9 TU of WIFPWIQL-phage, WDLAWMFRLPVG-phage, or negatained (Harlan-Sprague-Dawley, Indianapolis, IN). Prostate cancer xenotive control phage were incubated for 2 hr at RT. An anti-bacteriophage grafts were established by subcutaneous administration of human DU145 antibody (Sigma) was added to the slides (150 l of a 1:500 dilution) and cells (10 6 cells in 200 l DMEM) into the subcutaneous tissue of the nude incubated for 1 hr at RT. After three washes with TBST, the peroxidasemice. Immunocompetent female Balb/c mice bearing mouse EF43-fgf4-conjugated anti-rabbit secondary antibody was added. Slides were washed derived breast tumors were established as described (Deroanne et al., 1997;  three times with TBST, developed with DAB, counterstained by a 20 s Hajitou et al., 2001 Marchiò et al., 2004) . The Internal Animal Care immersion in 100% hematoxylin, dehydrated, and mounted. To test whether and Use Committee of the University of Texas M.D. Anderson Cancer Center the phage would block anti-GRP78 antibody staining, we proceeded as (UTMDACC) reviewed and approved all animal experimentation.
follows. First, after deparaffinization, rehydration, protein, and peroxidase blockages, 2 ϫ 10 9 TU of WIFPWIQL-phage, WDLAWMFRLPVG-phage, Tumor targeting in vivo negative control phage, or media alone were added to the slides and incuIn vivo targeting experiments with phage were performed as described (Arap bated for 2 hr. Next, anti-GRP78 antibody or control antibody at an equivalent et Koivunen et al., 1999; Kolonin et al., 2004; Marchiò et al., 2004;  immunoglobulin concentration was added to the slides and incubated for . Briefly, either male nude mice bearing size-matched 1 hr at RT. Slides were washed three times with TBST, and a peroxidasehuman DU145 xenografts or immunocompetent female Balb/c female mouse conjugated secondary antibody was added. After three washes, developbearing EF43-fgf4-derived breast tumors were deeply anesthetized and ment was achieved with the DAB substrate. Slides were counterstained by injected intravenously (tail vein) with 10 10 TU of WIFPWIQL-phage, WDL hematoxylin, dehydrated, and mounted. The Institutional Review Board (IRB) AWMFRLPVG-phage, RGD-4C phage (positive control), or fd-tet phage (negof the University of Sã o Paulo Medical School reviewed and approved all ative control) in vehicle (DMEM). Cohorts of three mice with size-matched experimentation in patient-derived samples. tumors received each set of phage clones. After 24 hr, tumor-bearing mice were perfused through the heart with 20 ml of 4% PFA. Tumor and control Statistical analysis organs were dissected from each mouse and fixed in PBS containing 4%
Experimental results are expressed as mean Ϯ standard errors of the mean PFA for 24 hr. Finally, tissues were paraffin embedded and sectioned into (SEM) of triplicate plates. Statistical significance was determined by Stu-5 m specimens for phage staining as described ). dent's t tests.
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